Literature DB >> 21795520

Characterization of FGF receptor expression in human neutrophils and their contribution to chemotaxis.

Lydia E Haddad1, Lara Bou Khzam, Fadi Hajjar, Yahye Merhi, Martin G Sirois.   

Abstract

Several members of the fibroblast growth factor (FGF) family are potent endothelial cell (EC) mitogens and angiogenic factors, and their activities can be mediated by four tyrosine kinase receptors (FGFR1-4). In addition, FGFs can induce the release of inflammatory mediators by ECs and the expression of adhesion molecules at their surface, thereby favoring the recruitment and transvascular migration of inflammatory cells such as neutrophils. Neither the expression nor the biological activities that could be mediated by FGFRs have been investigated in human neutrophils. By biochemical and cytological analyses, we observed that purified circulating human neutrophils from healthy individuals expressed varying levels of FGFRs in their cytosol and at their cytoplasmic membrane. FGFR-2 was identified as the sole cell surface receptor, with FGFR-1 and -4 localizing in the cytosol and FGFR-3 being undetectable. We assessed the capacity of FGF-1 and FGF-2 to induce neutrophil chemotaxis in a modified Boyden microchamber and observed that they increase neutrophil transmigration at 10(-10) and 10(-9) M and by 1.77- and 2.34-fold, respectively, as compared with PBS-treated cells. Treatment with a selective anti-FGFR-2 antibody reduced FGF-1-mediated chemotaxis by 75% and abrogated the effect of FGF-2, while the blockade of FGFR-1 and -4 partially inhibited (15-40%) FGF-chemotactic activities. In summary, our data are the first to report the expression of FGF receptors in human neutrophils, with FGF-1 and FGF-2 promoting neutrophil chemotaxis mainly through FGFR-2 activation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795520     DOI: 10.1152/ajpcell.00215.2011

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  12 in total

1.  Topical dobesilate eye drops for ophthalmic primary pterygium.

Authors:  Pedro Cuevas; Luis A Outeiriño; Javier Angulo; Guillermo Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-03-08

2.  FGF23 signaling impairs neutrophil recruitment and host defense during CKD.

Authors:  Jan Rossaint; Jessica Oehmichen; Hugo Van Aken; Stefan Reuter; Hermann J Pavenstädt; Melanie Meersch; Mark Unruh; Alexander Zarbock
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

3.  FGF1 alleviates LPS-induced acute lung injury via suppression of inflammation and oxidative stress.

Authors:  Qhaweni Dhlamini; Wei Wang; Guifeng Feng; Aiping Chen; Lei Chong; Xue Li; Quan Li; Jin Wu; Depu Zhou; Jie Wang; Hailin Zhang; Jin-San Zhang
Journal:  Mol Med       Date:  2022-06-28       Impact factor: 6.376

4.  Biomarkers of Mineral and Bone Metabolism and 20-Year Risk of Hospitalization With Infection: The Atherosclerosis Risk in Communities Study.

Authors:  Junichi Ishigami; Bernard G Jaar; Casey M Rebholz; Morgan E Grams; Erin D Michos; Myles Wolf; Csaba P Kovesdy; Shinichi Uchida; Josef Coresh; Pamela L Lutsey; Kunihiro Matsushita
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

5.  Fibroblast growth factor 23 weakens chemotaxis of human blood neutrophils in microfluidic devices.

Authors:  Ke Yang; Hagit Peretz-Soroka; Jiandong Wu; Ling Zhu; Xueling Cui; Michael Zhang; Claudio Rigatto; Yong Liu; Francis Lin
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

Review 6.  Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review.

Authors:  Usama A Sharaf El Din; Mona M Salem; Dina O Abdulazim
Journal:  J Adv Res       Date:  2017-02-27       Impact factor: 10.479

Review 7.  Role of Fibroblast Growth Factor-23 in Innate Immune Responses.

Authors:  Elizabeth A Fitzpatrick; Xiaobin Han; Zhousheng Xiao; L Darryl Quarles
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-12       Impact factor: 5.555

8.  Analysis of Polymorphisms in the Mediator Complex Subunit 13-like (Med13L) Gene in the Context of Immune Function and Development of Experimental Arthritis.

Authors:  Samra Sardar; Katrine Kanne; Åsa Andersson
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2018-06-27       Impact factor: 4.291

Review 9.  FGF23, Biomarker or Target?

Authors:  Cristian Rodelo-Haad; Rafael Santamaria; Juan R Muñoz-Castañeda; M Victoria Pendón-Ruiz de Mier; Alejandro Martin-Malo; Mariano Rodriguez
Journal:  Toxins (Basel)       Date:  2019-03-22       Impact factor: 4.546

Review 10.  FGF23 Actions on Target Tissues-With and Without Klotho.

Authors:  Beatrice Richter; Christian Faul
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.